Takeda commits to 65% increase in plasma manufacturing capacity to support business acquired in takeover of Shire.

Shire grew into a leader in plasma-derived therapies through its $32bn takeover of Baxalta, the Baxter spinoff that had a portfolio of such products and the infrastructure to manufacture them. Takeda took control of those assets at the start of the year when it completed its $62bn takeover of Shire.

Read more here.